Vistagen’s Fasedienol Phase 2 Data Due August 2026 for Social Anxiety
Vistagen's fasedienol Phase 2 data for social anxiety disorder readout set for August 2026 will determine next steps in...
FDA Approves Tudriqev for Anti-PD-1 Resistant Advanced Melanoma
FDA approves Tudriqev for anti-PD-1 resistant advanced melanoma, offering a new oncolytic viral therapy option for patients who failed...
When Your CRO’s AI Sends a Query, Who’s Accountable for the Answer?
ICON's Anthropic partnership deploys Claude into clinical trial monitoring. Here's what site coordinators and ops leads need to verify...
The PTSD Nightmare Drug No One Expected: What Dronabinol’s RCT Tells Us About CNS Trial Design
A dronabinol RCT in Nature Medicine just outperformed prazosin's VA trial with 170+ PTSD patients. Here's what the trial...
Tenaya’s TN-201 Gene Therapy Shows Hypertrophy Reduction in HCM Patients
TN-201 gene therapy reduces hypertrophy in all six evaluable HCM patients in MyPEAK-1 trial, targeting MYBPC3 mutation root cause.
Summit Therapeutics Launches HARMONi-GU1 Trial for Ivonescimab in Bladder Cancer
Summit Therapeutics launches HARMONi-GU1 trial testing ivonescimab bladder cancer treatment combining PD-1 and VEGF blockade with an antibody-drug conjugate.
Kymera’s KT-621 atopic dermatitis trial closes enrollment six months early
Kymera's KT-621 atopic dermatitis trial closes enrollment six months early, accelerating topline readout to year-end 2026.
NewAmsterdam Pharma Wins CHMP Opinion for Obicetrapib Cholesterol Drug
NewAmsterdam Pharma's obicetrapib cholesterol drug wins CHMP backing for EU authorization, with a 23% MACE reduction across Phase 3...
FDA Accepts daraxonrasib Application for RAS-Mutant Pancreatic Cancer
FDA accepts daraxonrasib application for RAS-mutant pancreatic cancer, following Phase 3 data showing 13.2-month median overall survival versus 6.7...
Lexeo Therapeutics’ LX2020 Receives FDA RMAT Designation for PKP2 Cardiomyopathy
Lexeo Therapeutics' LX2020 receives FDA RMAT designation for PKP2 cardiomyopathy, enabling expedited development and agency dialogue for the gene...